Amanote Research
Register
Sign In
Prm154 - Modeling Migraine Day Frequency by Responder Status: A Re-Analysis of Data From Erenumab Clinical Trials
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2274
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
JK Porter
D Burns
GL Di Tanna
RB Lipton
S Palmer
S Sapra
G Villa
Publisher
Elsevier BV
Related search
Pnd9 - Migraine Burden Before and After Erenumab Treatment: A Responder Analysis in Difficult-To-Treat Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Erenumab: A Monoclonal Antibody for Migraine Prophylaxis
Prescriber
Pharmacology
Migraine Day Frequency in Migraine Prevention: Longitudinal Modelling Approaches
BMC Medical Research Methodology
Epidemiology
Health Informatics
How Transparent Are Migraine Clinical Trials?: Repository of Registered Migraine Trials (RReMiT)
Neurology
Neurology
Development of Responder Definitions for Fibromyalgia Clinical Trials
Arthritis & Rheumatism
Sympathetic Nerve Blocks, Pragmatic Trials, and Responder Analysis
Anesthesiology
Anesthesiology
Pain Medicine
074 Early Australian Experience With Erenumab for Chronic Migraine
Journal of Neurology, Neurosurgery and Psychiatry
Psychiatry
Mental Health
Neurology
Surgery
International Comparison of Data From International Clinical Trials Registry Platform-Registered Clinical Trials
Health
Data Modeling Methods in Clinical Trials: Experiences From the Clinical Trial Methods in Neurodegenerative Diseases Project
Trials
Medicine
Pharmacology
